SG Americas Securities LLC purchased a new stake in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,360 shares of the company’s stock, valued at approximately $212,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. US Bancorp DE raised its holdings in Legend Biotech by 4.5% during the 1st quarter. US Bancorp DE now owns 6,835 shares of the company’s stock valued at $383,000 after buying an additional 293 shares during the last quarter. American International Group Inc. increased its position in Legend Biotech by 50.0% during the 1st quarter. American International Group Inc. now owns 900 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares during the period. Public Sector Pension Investment Board increased its position in Legend Biotech by 1.6% during the 2nd quarter. Public Sector Pension Investment Board now owns 24,689 shares of the company’s stock valued at $1,093,000 after purchasing an additional 400 shares during the period. ProShare Advisors LLC increased its position in Legend Biotech by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 5,585 shares of the company’s stock valued at $313,000 after purchasing an additional 494 shares during the period. Finally, Daiwa Securities Group Inc. increased its position in Legend Biotech by 9.0% during the 1st quarter. Daiwa Securities Group Inc. now owns 6,359 shares of the company’s stock valued at $356,000 after purchasing an additional 527 shares during the period. 70.89% of the stock is currently owned by institutional investors.
Legend Biotech Stock Up 3.6 %
NASDAQ:LEGN opened at $45.04 on Wednesday. The firm has a market cap of $8.21 billion, a P/E ratio of -34.64 and a beta of 0.10. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.78 and a current ratio of 4.84. Legend Biotech Co. has a fifty-two week low of $38.60 and a fifty-two week high of $70.13. The firm has a 50-day simple moving average of $50.94 and a two-hundred day simple moving average of $49.11.
Analysts Set New Price Targets
A number of brokerages have issued reports on LEGN. Royal Bank of Canada reissued an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a research report on Friday, September 27th. Scotiabank boosted their price objective on shares of Legend Biotech from $70.00 to $76.00 and gave the company a “sector outperform” rating in a research report on Monday, August 12th. BMO Capital Markets reissued an “outperform” rating and set a $90.00 price objective on shares of Legend Biotech in a research report on Wednesday, July 3rd. Redburn Atlantic began coverage on shares of Legend Biotech in a research report on Tuesday, October 8th. They set a “buy” rating and a $86.00 price objective on the stock. Finally, TD Cowen reduced their target price on shares of Legend Biotech from $71.00 to $67.00 and set a “buy” rating on the stock in a research report on Monday, July 15th. Fourteen equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $82.08.
Read Our Latest Report on Legend Biotech
Legend Biotech Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Read More
- Five stocks we like better than Legend Biotech
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What is a Bond Market Holiday? How to Invest and Trade
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding LEGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Legend Biotech Co. (NASDAQ:LEGN – Free Report).
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.